Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Google's proposed data center in orbit will face issues with space debris in an already crowded orbit - 2How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- 3Favored Vehicle for Seniors: Make Your Determination
- 46 Hints to Upgrade Your Appeal, In addition to Your Outlook
- 5From Fledgling to Master: Self-awareness in a Side interest
- At least 11 killed in South Africa mass shooting
- Lift Your Style: Famous Hairdos for Ladies
- Washington resident is infected with a different type of bird flu
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
- What's Your Number one Superhuman Film Made?
- 5 things for parents to know about changes to kids vaccine schedule
- The Most Vital Crossroads in Olympic History
- The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- 10 High priority Contraptions for Tech Aficionados
